SBIR/STTR Is Reauthorized Through 2031. The New $30 Million Strategic Breakthrough Award, Proposal Caps, and Foreign-Risk Screening Rewrite the Playing Field — Here Is What Changes Now.

For five and a half years, the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have lurched from short-term reauthorization to short-term reauthorization — three-year cycles, lapse threats, continuing-resolution gymnastics, and the structural anxiety that comes with running the federal government's largest seed-stage R&D program on a series of ticking clocks. That ended on April 13, 2026, when the President signed S. 3971 into law, extending SBIR and STTR authorization through September 30, 2031 — the longest extension in the programs' modern history.

The new authorization period is the headline, but it is not the most consequential change. The substance of the law is in five reforms that, taken together, reshape how small businesses, university spinouts, and dual-use technology startups will approach SBIR funding for the rest of the decade. Strategic Breakthrough Awards of up to $30 million per award introduce a new top tier of SBIR funding. Proposal caps starting in FY2027 will throttle the high-volume "SBIR mills" that have inflated submission counts at NIH and DoD. Expanded foreign-risk screening will eliminate applicants with certain ownership, partnership, or technology-licensing exposure. Phase III improvements are aimed at finally closing the long-criticized "Valley of Death" between Phase II completion and acquisition contracts. And technical-and-business-assistance (TABA) funding caps roughly double, expanding the support ecosystem.

Tracking the post-reauthorization rollout? Browse our SBIR/STTR Grants Hub for active agency solicitations, deadlines, and Phase II conversion data.

The Five-Year Authorization Is a Different Operating Environment

To understand why the duration of the reauthorization matters, consider what a three-year reauthorization actually meant for a small business pursuing SBIR funding. A Phase I award typically takes six to twelve months from solicitation to award. Phase II application and award typically takes another twelve months. Phase II execution runs 24 months. That sequence — roughly 48 months from initial application to Phase II completion — has been running against a 36-month authorization clock. Companies were investing in proposal pipelines without certainty that the program would still exist when their Phase II ended.

A five-and-a-half-year reauthorization removes that structural anxiety. Capital allocators inside small businesses can now plan two full Phase II cycles plus a Phase III commercial transition before the next authorization debate. Venture investors who have historically discounted SBIR pipelines because of authorization risk now have a cleaner case to back SBIR-led companies. And the universities and research institutions that increasingly partner with small businesses on STTR awards can build longer-term programs without re-litigating the funding source every cycle.

The strategic implication for applicants: the calculus for Phase II commitments has changed. A company weighing whether to take a Phase II award in 2027 no longer has to worry about whether the program will be reauthorized before Phase III contract vehicles can be exercised in 2029 or 2030. That stability is itself an asset.

Strategic Breakthrough Awards: The New $30M Top Tier

The most novel addition to the SBIR ecosystem is the Strategic Breakthrough Award, structured as a high-ceiling, high-match award for technology with national-security or critical-mission relevance. Each award can reach $30 million at agencies with extramural budgets exceeding $100 million, but the conditions are deliberately restrictive:

• The applicant must have already received a Phase II award (so this is a follow-on, not a new entry point)
• 100% matching funds are required from private capital or non-SBIR government sources
• Performance period is 48 months with a 90-day contracting window after award
• DoD-specific awards require program objective memorandum (POM) commitment and 20% matching from new DoD funding

The 100% match requirement is the key filter. A $30M award requires $30M in matching capital, which only a narrow set of companies can credibly raise: those with strong venture backing, those with strategic corporate investors, or those with established prime-contractor partnerships willing to co-invest. This is not a generally accessible award — it is a Phase III bridge for a small number of mature SBIR companies that need to scale a near-deployment technology.

For the broader SBIR community, Strategic Breakthrough Awards matter even if you cannot directly compete for them. Their existence reshapes what comes after Phase II: agencies will now expect the most mature Phase II awardees to pursue Strategic Breakthrough Awards as the natural next step, which in turn raises the bar for Phase II proposals to articulate a credible post-Phase-II commercial and transition path. The strategic framing in Phase II proposals — historically a "commercialization plan" section — needs to anticipate the SBA pathway upward.

Proposal Caps Starting FY2027: The End of the SBIR Mill

For a decade, a relatively small number of high-volume "SBIR mill" companies have submitted dozens or hundreds of proposals per year, winning a high absolute number of awards but a low per-proposal hit rate. The criticism — voiced by program managers, GAO reports, and academic researchers — has been that these companies optimize for proposal volume rather than technical merit, distorting agency review workloads and reducing the program's per-dollar innovation impact.

The new law directs agencies to establish proposal submission caps per company starting in FY2027, with waivers available for time-sensitive missions but limited to 5% of topics annually. The implementation details will vary by agency — NIH may use a different cap than DoD, and DoE may diverge again — but the direction is clear: high-volume applicants face hard limits on how many proposals they can submit per cycle.

For small businesses and first-time applicants, this is unambiguously good news. Reviewer workload at the proposal-evaluation phase has been a quiet drag on selection quality; reducing volume should improve the depth and consistency of reviews. For companies that have built revenue models around high-volume submission, the caps force a strategic shift toward fewer, better-aligned proposals.

The practical implication for any small business pursuing SBIR in 2027 and beyond: proposal portfolio strategy now matters more than proposal volume strategy. Picking the right two or three topics per cycle, aligning them carefully with company technology and capability, and investing serious effort in each — that approach will produce a better hit rate than blanket submission.

Foreign-Risk Screening Is Now Programmatic

The expanded foreign-security screening provisions are the most operationally consequential change for many companies. Applications will be denied based on connections to entities on UFLPA, Chinese Military-Industrial Complex, Section 889, Commerce Entity List, and similar watchlists. Due diligence requirements now include explicit assessment of:

• Cybersecurity posture
• Patent portfolio analysis
• Employee backgrounds (including dual citizenship and foreign academic affiliations)
• Foreign ownership structures (direct and beneficial)
• Technology licensing arrangements (inbound and outbound)

For companies that have raised capital from international investors, hired engineers with overseas academic backgrounds, or licensed technology from foreign institutions, the screening is a real risk. Some of these companies will need to restructure ownership, divest certain foreign positions, or formally exit certain partnerships before submitting future SBIR applications.

The practical implication: any small business considering an SBIR application should run an internal foreign-risk audit in 2026 — before submitting, not after a denial. Companies that discover screening risk only at the application stage typically cannot restructure quickly enough to win in the same cycle.

Phase III Improvements and the Valley of Death

The "Valley of Death" between SBIR Phase II completion and a follow-on production or sustainment contract has been the program's most persistent failure mode. Phase II ends with a working prototype and a commercialization plan; the path from prototype to production contract has historically been fragmented, slow, and dependent on the small business finding the right program office and the right contract vehicle.

The new law directs the SBA to:

• Establish workforce training for contracting officers on Phase III awards and data rights
• Require agencies to develop standardized procedures for Phase III conversions
• Grant small businesses direct access to requirements offices within agencies

These are structural reforms that will play out over years, not months. But they signal a serious congressional intent to fix the transition problem, and they create new openings for small businesses to engage agency requirements offices directly rather than through layers of prime contractors and intermediaries.

For companies currently in Phase II, the practical advice is to start mapping Phase III paths now — identifying the program offices that would naturally acquire the technology, the contract vehicles available, and the data-rights provisions that will govern the transition. The new law makes that mapping easier, but it does not do the mapping for you.

TABA Doubles: $6,500 Phase I, $50,000 Phase II

The Technical and Business Assistance (TABA) program — which lets SBIR awardees use a portion of their award to purchase technical, regulatory, or commercialization consulting — has historically been small enough that most awardees ignored it. The new caps roughly double the available funding: up to $6,500 for Phase I and up to $50,000 per project for Phase II, with the additional flexibility that awardees may select their own vendors or hire dedicated staff directly.

For first-time SBIR awardees, this matters more than the number suggests. A small biotech firm with a $1.5M Phase II award can now allocate $50K to a specialist regulatory consultant for FDA pre-submission strategy, or to a market-access consultant who can sharpen the commercialization plan, or to a part-time business-development hire. Those are exactly the gaps that have historically caused Phase II awardees to underperform in Phase III conversion.

The strategic shift: budget for TABA explicitly in Phase II applications, with named vendor categories or staff roles, rather than treating it as an afterthought. Reviewers will increasingly expect a credible TABA plan.

Expected Agency Rollout Through Summer 2026

Implementation of the new law will not be uniform across agencies. DoD is expected to move first — its SBIR/STTR Innovation Portal (DSIP) is already releasing FY26 topics under the post-reauthorization framework, and the DARPA BTO topics released April 30 reflect the new larger award envelopes. NIH and NSF are expected to release updated solicitations in late May and June 2026.

Companies actively pursuing SBIR funding in the next two cycles should expect:

• More frequent topic releases as agencies clear backlogs that built up during the authorization uncertainty
• Larger per-topic budgets at agencies that have the appropriations to support them
• Stricter pre-screening on foreign-risk and watchlist criteria, with denial coming earlier in the review cycle
• Clearer Phase III pathways at agencies that have embraced the SBA Phase III reforms

The five-week DARPA BTO window closing June 3 is one of the first tests of the new framework. The window is short, the topics are specific, and the awardees will be the first cohort to operate under the reauthorized program. For small businesses that have been waiting for stability, the stability has arrived.